Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

Eli Lilly’s cholesterol pill impressed in a mid-stage trial. Meanwhile, Dexcom invested $75 million in Oura.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.